Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19992919 | 0.89 | HSD17B10 (0.37) | HSD17B10SMN1; SMN2CPN1CPB2SLC6A9 | |
| SCHEMBL15496585 | 0.86 | HSD17B10 (0.37) | HSD17B10SLC6A9S1PR1ITGB3ITGA2B | |
| SCHEMBL8282582 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CPN1CPB2SLC6A9 | |
| SCHEMBL19841834 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CPN1CPB2SLC6A9 | |
| SCHEMBL15247296 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2CPN1CPB2 | |
| SCHEMBL21450627 | 0.83 | HSD17B10 (0.37) | HSD17B10SMN1; SMN2SLC6A9GSK3B | |
| SCHEMBL2603216 | 0.82 | KDM4E (0.47) | SMN1; SMN2CPN1CPB2 | |
| SCHEMBL22794329 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2BACE1 | |
| SCHEMBL26890387 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2BACE1 | |
| SCHEMBL19184868 | 0.82 | ITGB3 (0.37) | CPN1CPB2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180502-B2 | Azaspiro[4.5]decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210323970-A1 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-21 | — | — | US | disclosed |
| US-11001650-B2 | Electron donor for polyolefin polymerization catalysts and uses thereof | BRASKEM AMERICA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-10851111-B2 | Method for producing a spirooxindole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10730866-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200172548-A9 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-10030028-B2 | Method for producing a spirooxindole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-24 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | HSD17B10 3082/4885SMN1; SMN2 2862/4885CPN1 3979/4885 |
| US-10030028-B2 | Method for producing a spirooxindole derivative | MDM2, TP53, RB1 | HSD17B10 1652/4885SMN1; SMN2 4855/4885CPN1 2057/4885 |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | HSD17B10 4104/4885SMN1; SMN2 364/4885CPN1 2604/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HSD17B10 255/4885SMN1; SMN2 4707/4885CPN1 264/4885 |
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | HSD17B10 3082/4885SMN1; SMN2 2862/4885CPN1 3979/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HSD17B10 255/4885SMN1; SMN2 4707/4885CPN1 264/4885 |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR2, S1PR5 | HSD17B10 3070/4885SMN1; SMN2 2803/4885CPN1 4424/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | HSD17B10 2512/4885SMN1; SMN2 4041/4885CPN1 3100/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | HSD17B10 3493/4885SMN1; SMN2 426/4885CPN1 3775/4885 |
| US-11180502-B2 | Azaspiro[4.5]decane derivatives and use thereof | TRPV1, SCN5A, TRPA1 | HSD17B10 1559/4885SMN1; SMN2 630/4885CPN1 4766/4885 |
| US-10730866-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | HSD17B10 3408/4885SMN1; SMN2 780/4885CPN1 4664/4885 |
| US-11001650-B2 | Electron donor for polyolefin polymerization catalysts and uses thereof | PARG, PUF60, PARP1 | HSD17B10 1997/4885SMN1; SMN2 2509/4885CPN1 2346/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | HSD17B10 3493/4885SMN1; SMN2 426/4885CPN1 3775/4885 |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | HSD17B10 3082/4885SMN1; SMN2 2862/4885CPN1 3979/4885 |
| US-20210323970-A1 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | HSD17B10 1652/4885SMN1; SMN2 4855/4885CPN1 2097/4885 |
| US-10851111-B2 | Method for producing a spirooxindole derivative | MDM2, TP53, RB1 | HSD17B10 1652/4885SMN1; SMN2 4855/4885CPN1 2097/4885 |
| US-20200172548-A9 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | HSD17B10 1652/4885SMN1; SMN2 4855/4885CPN1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.